---
title: "Ozempic vs Wegovy: What's the Difference?"
description: "Compare Ozempic and Wegovy—two semaglutide medications. Learn about dosages, approved uses, insurance coverage, and which might be right for you."
publishedAt: "2024-01-20"
updatedAt: "2025-02-21"
author: "sarah-mitchell"
medicalReviewer: "james-chen"
category: "Comparisons"
tags: ["ozempic", "wegovy", "semaglutide", "comparison", "glp-1"]
featured: true
---

## Ozempic vs Wegovy: Understanding the Differences

Ozempic and Wegovy are both brand names for semaglutide, but they're approved for different uses and have some key differences. This guide will help you understand which might be appropriate for your situation.

## What They Have in Common

### Same Active Ingredient
Both medications contain semaglutide, a GLP-1 receptor agonist that:
- Reduces appetite
- Slows gastric emptying
- Regulates blood sugar
- Promotes significant weight loss

### Same Manufacturer
Both are produced by Novo Nordisk, a Danish pharmaceutical company specializing in diabetes care.

### Similar Administration
- Weekly subcutaneous injections
- Pre-filled injection pens
- Self-administered at home

## Key Differences

### FDA-Approved Indications

| Feature | Ozempic | Wegovy |
|---------|---------|--------|
| **Primary Use** | Type 2 Diabetes | Chronic Weight Management |
| **BMI Requirements** | None (diabetes diagnosis) | ≥30 or ≥27 with comorbidity |
| **Age Approval** | Adults 18+ | Adults 18+, Children 12+ |

> **Evidence:** "Semaglutide is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to consider. Ozempic® injection is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events. Wegovy® injection is FDA-approved for promoting weight loss in individuals dealing with obesity and overweight." — *Kommu S, Whitfield P. StatPearls. 2024.* [DOI](https://www.ncbi.nlm.nih.gov/books/NBK603723/)

> **Evidence:** "In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight." — *Wilding JPH, et al. STEP 1 Study Group. N Engl J Med. 2021.* [DOI](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)

### Dosage Differences

**Ozempic Dosing:**
- Starts at 0.25 mg weekly
- Maximum: 2.0 mg weekly

**Wegovy Dosing:**
- Starts at 0.25 mg weekly
- Maximum: 2.4 mg weekly

The higher maximum dose of Wegovy (2.4 mg vs 2.0 mg) contributes to greater average weight loss.

> **Evidence:** "Semaglutide is recommended for treating T2D in a dose of 0.5 mg–1.0 mg and possible escalation up to 2 mg, whilst a 2.4 mg dose of semaglutide is recommended for obesity." — *Singh A, et al. Diabetes Metab Syndr. 2025.* [DOI](https://doi.org/10.1016/j.dsx.2025.103212)

### Pen Design

**Ozempic:**
- 1 mg and 2 mg pen options
- Each pen contains multiple doses
- Different click counts for different doses

**Wegovy:**
- Single-use pens for each dose
- 5 different pen strengths
- Color-coded for each dose level
- No dose counting needed

## Effectiveness Comparison

### Weight Loss Results

**Wegovy (STEP Trials):**
- Average weight loss: 15-17% of body weight
- 68-week treatment period

> **Evidence:** "The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo, for an estimated treatment difference of −12.4 percentage points. More participants in the semaglutide group than in the placebo group achieved weight reductions of 5% or more (86.4% vs. 31.5%), 10% or more (69.1% vs. 12.0%), and 15% or more (50.5% vs. 4.9%)." — *Wilding JPH, et al. STEP 1 Study Group. N Engl J Med. 2021.* [DOI](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)

**Ozempic (SUSTAIN Trials):**
- Average weight loss: 9-14% of body weight
- Secondary outcome in diabetes trials

> **Evidence:** "At week 104, among patients receiving semaglutide, the mean body weight decreased from 92.1 kg at baseline to 88.5 kg in the group receiving 0.5 mg and to 87.2 kg in the group receiving 1.0 mg, for changes of −3.6 kg and −4.9 kg, respectively." — *Marso SP, et al. SUSTAIN-6 Investigators. N Engl J Med. 2016.* [DOI](https://www.nejm.org/doi/full/10.1056/NEJMoa1607141)

### Blood Sugar Control

**Ozempic:**
- HbA1c reduction: 1.0-1.5%
- Primary indication is diabetes management

> **Evidence:** "At week 104, among patients receiving semaglutide, the mean glycated hemoglobin level decreased from 8.7% at baseline to 7.6% in the group receiving 0.5 mg and to 7.3% in the group receiving 1.0 mg, for changes of −1.1% and −1.4%, respectively." — *Marso SP, et al. SUSTAIN-6 Investigators. N Engl J Med. 2016.* [DOI](https://www.nejm.org/doi/full/10.1056/NEJMoa1607141)

**Wegovy:**
- Some blood sugar benefits
- Not primarily a diabetes medication

## Insurance Coverage

### Ozempic
- Generally covered for type 2 diabetes
- May require step therapy (try other medications first)
- Prior authorization often needed

### Wegovy
- Coverage varies significantly by plan
- Many insurers require documented weight loss attempts
- Some exclude weight loss medications entirely
- Medicare does not cover weight loss drugs

### Cost Without Insurance
- Ozempic: ~$935/month
- Wegovy: ~$1,349/month

## Side Effects

Both medications have similar side effect profiles since they contain the same active ingredient:

### Common Side Effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain

### Serious Risks
- Thyroid C-cell tumors (boxed warning)
- Pancreatitis
- Gallbladder disease
- Kidney injury
- Diabetic retinopathy complications

## Which Should You Choose?

### Choose Ozempic If:
- You have type 2 diabetes
- Your insurance covers it for diabetes
- You want blood sugar control plus weight loss
- 2.0 mg dose provides adequate weight loss

### Choose Wegovy If:
- Your primary goal is weight loss
- You don't have diabetes
- You qualify based on BMI requirements
- You want maximum weight loss potential
- Your insurance covers weight management medications

## Off-Label Use

Many providers prescribe Ozempic off-label for weight loss when:
- Wegovy is unavailable (supply shortages)
- Insurance won't cover Wegovy
- Patient prefers the Ozempic pen design

This is legal and common, though not FDA-approved.

## Supply Availability

Both medications have experienced shortages due to high demand. Check current availability:
- FDA drug shortage database
- Pharmacy stock checks
- Manufacturer websites

## Switching Between Them

Switching is possible under medical supervision:
- Dose conversion may be needed
- Titrate up if increasing dose
- Monitor for side effects
- Insurance considerations

## Conclusion

Ozempic and Wegovy are essentially the same medication with different approved uses and maximum doses. Your choice depends on:
1. Your medical conditions
2. Insurance coverage
3. Availability
4. Doctor recommendation

Consult with your healthcare provider to determine the best option for your individual circumstances.

---

## References

1. **Kommu S, Whitfield P.** Semaglutide. *StatPearls [Internet].* Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: [PubMed](https://www.ncbi.nlm.nih.gov/books/NBK603723/)

2. **Wilding JPH, Batterham RL, Calanna S, et al.** Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. [DOI: 10.1056/NEJMoa2032183](https://doi.org/10.1056/NEJMoa2032183)

3. **Marso SP, Bain SC, Consoli A, et al.** Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 2016;375(19):1834-1844. [DOI: 10.1056/NEJMoa1607141](https://doi.org/10.1056/NEJMoa1607141)

4. **Singh A, Singh R, Singh AK, Misra A.** Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials. *Diabetes Metab Syndr.* 2025;19(3):103212. [DOI: 10.1016/j.dsx.2025.103212](https://doi.org/10.1016/j.dsx.2025.103212)
